Skip to main content

Ronapreve

Question for Department of Health and Social Care

UIN 9075, tabled on 25 May 2022

To ask the Secretary of State for Health and Social Care, whether the Government has (a) made an assessment of which groups of immunosuppressed patients should be eligible for treatment with the drug, Ronapreve, as a result of their lack of response to the covid-19 vaccine and (b) plans to undertake antibody testing on those individuals to assess their response to that drug.

Answered on

7 June 2022

While the Medicines and Healthcare products Regulatory Agency has approved Ronapreve for prophylaxis, the treatment has since been found to be ineffective against the Omicron variant and therefore has been withdrawn from general use. There are currently no plans to implement targeted antibody testing for immunocompromised patients. National Health Service clinicians can arrange antibody testing for patients based on their assessment of clinical need.